A Bispecific Immunotherapy for the Treatment of Melanoma

April 24, 2015
Mark R. Middleton, MD, PhD

Mark R. Middleton, MD, PhD, discusses the results of a phase I/IIa trial of IMCgp100, a bispecific immunotherapy, for the treatment of patients with melanoma.

Mark R. Middleton, MD, PhD, a professor of experimental cancer medicine at the University of Oxford, discusses the results of a phase I/IIa trial of IMCgp100, a bispecific immunotherapy, for the treatment of patients with melanoma.

<<<

View more from the 2015 AACR Annual Meeting